ACADIA Pharmaceuticals Appoints John J. Kaiser as Vice President, Strategic Marketing and Commercial Development
SAN DIEGO, Feb 12, 2008 (BUSINESS WIRE) — ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced the appointment of John J. Kaiser as Vice President, Strategic Marketing and Commercial Development. Mr. Kaiser joins ACADIA from Eli Lilly & Co. where he held a variety of marketing and commercial management positions over a more than 25-year career.
“John’s extensive CNS marketing and commercial experience will be a tremendous asset to ACADIA as we execute on our strategy to develop and commercialize pimavanserin together with a strategic partner and prepare ACADIA to participate in the future commercialization of pimavanserin within the U.S. neurology market,” said Uli Hacksell, Ph.D., ACADIA’s Chief Executive Officer.
Prior to joining ACADIA, Mr. Kaiser served as Director, Neuroscience Strategy and New Product Planning where he was responsible for the development of Eli Lilly’s global neuroscience commercial strategy. Previously, he held senior level positions in global commercial development, market research, and brand management. In these various roles, Mr. Kaiser was responsible for establishing the business and brand strategy for Cymbalta(R), developing global market research in support of the successful launch of Zyprexa(R), and managing the global Prozac(R) brand and associated marketing activities. Earlier in his career at Lilly, he served as Managing Director of Eli Lilly Netherlands, and held a variety of positions in pharmaceutical sales and sales management. Mr. Kaiser earned a Bachelors of Science in Pharmacy from the University of Cincinnati College of Pharmacy.
“I look forward to bringing my experiences and network to bear on the development and commercialization of pimavanserin and ACADIA’s portfolio of neuroscience assets,” said Mr. Kaiser. “These drug candidates have the potential to offer patients with mental illness significant opportunities for improved outcomes and quality of life.”
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has five mid-to-late stage clinical programs as well as a portfolio of preclinical and discovery assets directed at diseases with large unmet medical needs, including schizophrenia, Parkinson’s disease psychosis, sleep maintenance insomnia, and neuropathic pain. All of the drug candidates in ACADIA’s product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA’s corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmo, Sweden.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to the benefits to be derived from ACADIA’s drug development programs, including the potential benefits to patients with mental illness, ACADIA’s strategy to establish a strategic partnership to develop and commercialize pimavanserin and its strategy to participate in the future commercialization of pimavanserin within the U.S. neurology market. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to ACADIA’s annual report on Form 10-K for the year ended December 31, 2006 as well as ACADIA’s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Uli Hacksell, Ph.D., Chief Executive Officer